AMGN : Analysis & Opinions

  1. Agenus Jumps on Positive Data from Shingles Candidate - Analyst ...

    December 19, 2014
    Shares of Agenus Inc. (AGEN) jumped after its partner GlaxoSmithKline (GSK) announced encouraging results on HZ/su.
  2. Seattle Genetics Initiates Phase Ib Study on Leukemia Drug - ...

    December 19, 2014
    Seattle Genetics, Inc. (SGEN) has initiated a phase Ib study on SGN-CD33A for newly diagnosed acute myeloid leukemia.
  3. Halozyme Up on Collaboration and Licensing Deal with J&J - Analyst ...

    December 18, 2014
    Shares of Halozyme (HALO) jumped after announcing a worldwide collaboration and license agreement with Johnson & Johnson ...
  4. Novartis Successfully Expands Signifor Label in the U.S. - Analyst ...

    December 17, 2014
    Novartis's (NVS) Signifor long-acting release was approved in the U.S. for the acromegaly indication.
  5. Alkermes Starts Phase I Study on Schizophrenia Candidate - Analyst ...

    December 16, 2014
    Alkermes (ALKS) announced the commencement of a phase I extended dosing study on aripiprazole lauroxil for the treatment ...
  6. Acorda's Ampyra in Phase III for Post-Stroke Walking Deficit ...

    December 16, 2014
    Acorda (ACOR) has commenced a phase III study on Ampyra for the treatment of post-stroke walking deficits.
  7. Is Illumina (ILMN) Worth Adding to Your Portfolio? - Analyst ...

    December 16, 2014
    On Dec 10, 2014, we issued an updated research report on Illumina Inc. (ILMN).
  8. 4 Top Ranked Biotech Stocks that Beat the Market in 2014 - Analyst ...

    December 16, 2014
    Despite the sell-off in late March, the biotech sector bounced back thanks to important product approvals, mergers and acquisitions, ...
  9. Stock Market News for December 16, 2014 - Market News

    December 16, 2014
    Markets finished a choppy session in the negative territory on Monday as yet another slide in oil prices dented investor ...
  10. Alexion's Soliris Receives Orphan Drug Status in Japan - Analyst ...

    December 15, 2014
    Alexion (ALXN) announced that Soliris has received orphan drug designation in Japan for the treatment of myasthenia gravis.
  11. Jazz Pharmaceuticals Starts Defibrotide Rolling NDA Filing - ...

    December 15, 2014
    Jazz Pharmaceuticals (JAZZ) has started the rolling submission of a NDA for defibrotide.
  12. Alnylam Provides Pipeline Update, Growth Strategy - Analyst Blog

    December 15, 2014
    Alnylam (ALNY) announced a strategy for developing its RNAi therapeutics in three strategic therapeutic areas (STArs): genetic ...
  13. Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook

    November 18, 2014
    Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
  14. S&P Down 3% - What's on Sale? - Ahead of Wall Street

    August 4, 2014
    Solid Q2 earnings across most sectors this season justified the long run-up in the stock market, and we had been expecting ...
  15. Bull of the Day: Amgen (AMGN) - Bull of the Day

    March 31, 2014
    Bull of the Day: Amgen (AMGN) - Bull of the Day
  16. Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook

    March 25, 2014
    Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
  17. Bull of the Day: Quintiles (Q) - Bull of the Day

    March 5, 2014
    Bull of the Day: Quintiles (Q) - Bull of the Day
  18. Biotech Stock Roundup: Amgen Data Looks Good, CANF Tumbles - ...

    January 8, 2014
    Biotech Stock Roundup: Amgen Data Looks Good, CANF Tumbles - Industry Outlook
  19. Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook

    December 3, 2013
    Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook
  20. 7 ETF Types To Be Thankful For

    November 28, 2013
    This year has shaped up to be quite kind to investors as major equity indexes are holding onto double-digit gains ahead of ...
  21. Despite the healthcare sectors recent torrid run, there’s still plenty to like about stocks in the industry.

    A Strong Prognosis For Healthcare Stocks

    November 19, 2013
    Despite the healthcare sectors recent torrid run, there’s still plenty to like about stocks in the industry. Aside from tailwinds ...
  22. Gilead Sciences Leads In Rising Short Interest Among Biotechs

    November 12, 2013
    Among leading biotech and emerging pharmaceutical companies, the number of shares sold short in Alexion Pharmaceuticals ...
  23. Alexion, Pharmacyclics Buck Trend in Biotech Short Interest (ALXN, ...

    September 14, 2013
    Declining short interest in Alexion Pharmaceuticals (NASDAQ: PCYC) bucked the trend among leading biotech and emerging pharmaceutical ...
  24. Amgen Sweetens The Bid And Secures Onyx

    August 26, 2013
    Amgen finalizes a value-additive deal for Onyx
  25. Can Sanofi Investors Just Blame It On Rio?

    August 6, 2013
    Can Sanofi Investors Just Blame It On Rio? By Stephen D. Simpson, CFA Sanofi (NYSE: SNY) was supposed to be a relatively ...
  26. Does Amgen Deserve To Be Part Of The Biotech Bull Run?

    July 31, 2013
    Amgen is beating growth targets today, but fears about generics and a dull pipeline concern investors.
  27. Wall Street Happy To Hum La AbbVie En Rose

    July 26, 2013
    AbbVie's pipeline is better than some think, but valuation is no particular bargain right now.
  28. Amgen Puts Onyx Pharmaceuticals In Play

    July 2, 2013
    An unsolicited $120/share bid has sent Onyx soaring and rival bidders circling.
  29. Biotech ETFs Surge as Onyx Rejects Amgen Offer - ETF News And ...

    July 1, 2013
    Biotechnlogy ETFs are moving higher as Onyx had rejected a takeover bid by Amgen, pushing securities up across the board. ...
  30. Short Interest in Biogen Idec and Vertex Shrinks (BIIB, CELG, ...

    June 26, 2013
    Among biotech and emerging pharmaceutical companies, Celgene (NASDAQ: CELG) and saw the most significant rise in short interest ...
  31. 3 Impressive Biotech ETFs Crushing the Market - ETF News And ...

    June 11, 2013
    Rotate into the outperforming biotech sector with these three ETFs.
  32. 10 Picks from 2 Strong Sectors

    June 10, 2013
    As we enter the bumpy summer months, large-cap US domestic stocks and health-care names are on Louis Navellier's list, and ...
  33. Alnylam Basking In Orphan Drug Attention

    May 28, 2013
    Alnylam has already seen a big run, but clinical success could bring even more gains.
  34. Amgen Chased By The Bubble

    May 8, 2013
    Amgen really needs the pipeline to come through to support this valuation.
  35. Teva Likely To Tread Water Ahead Of New Strategy

    November 5, 2012
    Teva has restructuring and growth opportunities, but the risk is still elevated.
  36. Amgen and Other Healthcare Stocks Making Big Moves on October ...

    October 19, 2012
    The market is having a bad day so far: the Nasdaq has slipped 1.6%; the S&P 500 is trading down 1%; and the Dow is down ...
  37. It's Time to Sell These 4 Surging Stocks

    October 19, 2012
    With the S&P 500 surging roughly 25% in the past 12 months, it's been a great time to have full exposure to the stock ...
  38. The Week In Healthcare

    August 31, 2012
    Although this has been a solid year for med-tech, some sub-sectors are starting to lag a bit during this late summer rally. ...
  39. 5 Familiar Stocks to Sell (or Short)! - Investment Ideas

    August 3, 2012
    Like so many people around the planet, I tuned into some Olympic action over the weekend. Ever since childhood, I have enjoyed ...
  40. Portfolio Pruning 101

    July 27, 2012
    MoneyShow's Tom Aspray takes an in-depth look at his successful Charts in Play Portfolio, as he looks to take profits on ...
  41. DaVita to Settle Epogen Lawsuit - Analyst Blog

    July 6, 2012
    Recently, DaVita Inc. (DVA) agreed to pay $55 million in a bid to settle a lawsuit, indicting it for overuse of Amgen Inc's ...
  42. ilent Pays A Hefty Price For A Fixer-Upper Diagnostics Company

    May 22, 2012
    Agilent is paying up to get into the increasingly crowded diagnostics market.
  43. Biotech ETFs Hitting Highs

    May 17, 2012
    Biotech ETFs are hitting all-time highs and XBI looks like the best of the group. Because the ETF is already up 25% in 2 ...
  44. AstraZeneca Searches For Answers

    May 3, 2012
    AstraZeneca has an opportunity to do something big when it brings in a new CEO.
  45. 4 ETFs On Fire Right Now

    February 3, 2012
    The commodities market had some of the best-performing ETFs of January.
  46. Big Buys In Share Buybacks

    January 27, 2012
    Record corporate profits and super low interest rates are resulting in a shrinking market environment and a rise in share ...
  47. Be Your Own Venture Capitalist With These Stocks

    September 16, 2011
    By doing some digging, there are ways for the average joe to become his/her own venture capital fund.
  48. A Deal At Last For Sanofi And Genzyme

    February 18, 2011
    Though Sanofi finally got its way in acquiring Genzyme, time will determine if stockholders will truly benefit.
  49. Top-Heavy Pharmaceuticals

    August 27, 2010
    Investors should keep an eye on how much drug companies rely on its top sellers.
  50. Getting In On Growth At A Great Price

    July 5, 2010
    Here are some growth-oriented stocks with below-market average P/Es that investors can pick up during this shaky market to ...
  51. Biotech Bargains

    June 17, 2010
    High-growth biotech stocks are now priced like value plays.
  52. The 5 Most Important Drugs In America

    July 28, 2009
    A look at the top-selling drugs finds that a few that make more of a difference to the company's bottom line than others. ...
  53. Two More Reasons To Diversify

    June 3, 2009
    GM and Citigroup being removed from the DJIA should cause investors to focus on diversification.
  54. Convertible Securities In Today's Market

    April 30, 2009
    John Calamos, the father of convertible investing, moderated a panel on convertible bonds at the Milken Global Conference ...
  55. Dark Horse Candidates To Enter The Dow

    March 4, 2009
    The DJIA is sure to be rebalanced over the next year as some members teeter on bankruptcy or face falling from the index. ...
  56. Buyer Beware In Biotech ETFs

    August 27, 2007
    The biotech sector has been flat this year, and the five biotech ETFs have been hit and miss - mainly miss.
  57. Up on Amgen (AMGN)

    April 30, 2007
    Amgen shares are in a rut, and that could signal opportunity for investors.
Trading Center